A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)

Overview

Post-marketing commitment to the European Medicines Agency to conduct a prospective, controlled study of the transfer from Subutex to Suboxone.

Full Title of Study: “A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects”

Study Type

• Study Type: Interventional
• Study Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Primary Purpose: Treatment
  • Masking: Triple (Participant, Investigator, Outcomes Assessor)
• Study Primary Completion Date: April 2009

Interventions

• Drug: Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484
  • Suboxone sublingual tablet 4 mg/1 mg – 24 mg/6 mg, daily for 28 days
• Drug: Subutex, Buprenorphine Hydrochloride, SCH 28444
  • Subutex sublingual tablet 4-24 mg, daily for 28 days

Arms, Groups and Cohorts

• Active Comparator: Suboxone
  • Double-blind, once-daily sublingual Suboxone (buprenorphine/naloxone 4 mg/1 mg to 24 mg/6 mg) plus matching Subutex placebo during Week 1 followed by open-label, once-daily sublingual Suboxone (buprenorphine/naloxone 4 mg/1 mg to 24 mg/6 mg) during Weeks 2-4 with weekly access to take-home doses as of Week 2.
• Active Comparator: Subutex
  • Double-blind, once-daily sublingual Subutex (buprenorphine 4 mg to 24 mg) plus matching Suboxone placebo during Week 1 followed by open-label, once-daily sublingual Subutex (buprenorphine 4 mg to 24 mg) during Weeks 2-4 with weekly access to take-home doses as of Week 2.

Clinical Trial Outcome Measures

Primary Measures

• Response Rate
  • Time Frame: Assessed by Day 7 of double-blind, double-dummy treatment period.
  • Response rate was defined as the percentage of participants who did not receive a dose increase from the dose given at the first dosing date by Day 7 of a one-week, randomized, double-blind, double-dummy treatment transfer phase.

Participating in This Clinical Trial

Inclusion Criteria

• Subjects must be males or non-pregnant, non-lactating females. – Subjects must be at least 15 years of age, of either sex, and any race. – Subjects (and/or the parent or guardian for subjects under the age of legal consent or who otherwise are unable to provide independent consent) must demonstrate willingness to participate in the study and to adhere to dose and visit schedules. – Subjects must meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria(18) for opioid dependence. – Subjects must have been receiving maintenance treatment with Subutex at doses ranging from 4 mg to the maximum dose permitted by country labeling requirements, but not to exceed 24 mg/day, for at least 1 month prior to screening. – Subjects must not, according to self-report, have injected opioids more than four times in the month prior to screening. – Subjects must have an opioid-negative urine drug screening (UDS) result prior to randomization. – Each subject must confirm that he or she is practicing adequate contraception. – Female subjects of childbearing potential must have a negative urine beta-human chorionic gonadotropin (β-hCG) test prior to enrollment in the study. Exclusion Criteria:

• Subjects for whom treatment with either Subutex or Suboxone as required in the protocol would be inconsistent with national labeling. – Subjects who are unwilling or unable to comply with the requirements of the protocol (eg, pending incarceration) or are in a situation or condition that, in the opinion of the investigator, may interfere with participation in the study. – Subjects who are participating in any other clinical study in which medication(s) are being delivered. – Subjects with known allergy or sensitivity to naloxone. – Subjects who are on the staff, affiliated with, or a family member of the staff personnel directly involved with this study. – Subjects must not have serious untreated Axis I DSM-IV-TR psychiatric comorbidity (eg, those who are actively suicidal or homicidal, have untreated schizophrenia, etc). Polysubstance abuse or dependence will not exclude subjects except in the case of unauthorized and significant benzodiazepine use requiring medical detoxification or alcohol dependence requiring medical detoxification. – Human immunodeficiency virus (HIV)-positive subjects with clinical acquired immunodeficiency syndrome (AIDS). – Subjects treated with generic buprenorphine.

Gender Eligibility: All

Minimum Age: 15 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

• Lead Sponsor
  • Indivior Inc.
• Provider of Information About this Clinical Study
  • Sponsor